Volume 21, Number 10—October 2015
Methicillin-Susceptible, Vancomycin-Resistant Staphylococcus aureus, Brazil
Acquisition of high-level vancomycin resistance by Staphylococcus aureus represents a major public health risk because this antimicrobial drug continues to be the first-line and most inexpensive therapy to treat methicillin-resistant S. aureus (MRSA) despite concerns about its clinical efficacy. Recently, we described vancomycin-resistant MRSA (VR-MRSA) recovered from the bloodstream of a patient in Brazil (1). VR-MRSA belongs to sequence type (ST) 8 and is phylogenetically related to the community-associated (CA) MRSA USA300 genetic lineage that has rapidly disseminated in the United States and the northern region of South America (USA300-Latin American variant [USA300-LV]) (1,2). The vanA gene cluster in VR-MRSA was carried by a transferable staphylococcal plasmid (pBRZ01). We characterized a clinical isolate of vancomycin-resistant, methicillin-susceptible S. aureus (VR-MSSA) and document the in vivo transfer of the vanA gene cluster to 2 unrelated S. aureus strains causing bacteremia within the same patient.
On August 28, 2012, a blood culture from a patient in Brazil was reported positive for 2 isolates of MSSA while the patient was receiving daptomycin therapy (Technical Appendix[PDF - 745 KB - 11 pages]). One MSSA isolate was susceptible to all antimicrobial drugs tested (VS-MSSA). The second isolate (VR-MSSA) had a vancomycin MIC of 256 µg/mL and was also resistant to gentamicin (Table 1). Both isolates were susceptible to daptomycin (MIC 0.5 μg/mL). Thirteen days earlier, 2 MRSA isolates, 1 of which was resistant to vancomycin (VR-MRSA), were recovered from the blood of the same patient (Technical Appendix[PDF - 745 KB - 11 pages]) (1). The daptomycin MICs for both MRSA strains were also 0.5 μg/mL.
Bacterial strains used in this study (Table 1) were grown in brain–heart infusion broth and agar. Plasmid pBRZ01 was transferred by using filter mating (3) and VR-MSSA and VR-MRSA as donors and VS-MSSA, VS-MRSA, and RN4220RF as recipients (Table 1). Transconjugants were selected on brain heart infusion medium containing vancomycin (32 µg/mL) and fusidic acid (25 µg/mL). Colonies from each mating experiment were subjected to digestion withSmaI and pulsed-field gel electrophoresis to investigate genetic relatedness (1). Plasmids carrying the vanA gene cluster were detected by using S1 nuclease digestion followed by hybridization with a vanA probe (4).
Whole-genome sequencing of VR-MSSA, VS-MSSA, and 2 representatives of the Chilean/Cordobes clone (M1, M91) was performed by using MiSeq PacBio RS II (Illumina, San Diego, CA, USA) to close the VR-MSSA genome (5) (online Technical Appendix). Phylogenetic analysis was performed by using the maximum-likelihood framework within RAxML v7.4.2 (6). For cell wall analysis, extraction and separation of peptidoglycan precursors was performed as described (7).
The PFGE patterns of both isolates (VR-MSSA and VS-MSSA) were indistinguishable, and in vitro growth rates were similar (Figure 1, panel A). S1 nuclease analyses indicated that VR-MSSA harbored a plasmid of ≈55 kb, which yielded a positive result when hybridized with a vanA probe (Figure 1, panels B, C) and was similar in size to the previously described vanA-containing plasmid pBRZ01 identified in the same patient (1). pBRZ01 of VR-MSSA was readily transferred to S. aureus RN4220-RF (efficiency = 3 × 10−5/donor). In vitro conjugative transfer of pBRZ01 between MRSA and MSSA strains recovered from the patient’s bloodstream was also readily achieved with efficiencies ranging from 4.3 × 10−7/donor to 2.5 × 10−6/donor. Acquisition of the pBRZ01 by corresponding strains resulted in resistance to vancomycin and gentamicin (Table 1).
Genome sequencing (Technical Appendix[PDF - 745 KB - 11 pages]) showed that VR-MSSA and VS-MSSA belong to clonal complex (CC) 5 (sequence type ST5) and harbor staphylococcal protein A (Spa) type t002. VS-MSSA and VR-MSSA have the characteristic CC5 genetic traits described by Kos et al. (8). The genome of VR-MSSA has a 2,906,602-bp chromosome and 3 extrachromosomal elements, including a plasmid of 55,713 bp identical to the previously described vanA-carrying pBRZ01 (1), which also harbors aac(6′)-aph(2′′), which confers gentamicin resistance.
Comparison of the core genomes of VR-MSSA and VS-MSSA showed only 20 single-nucleotide polymorphism differences, which suggested a close genetic relationship and probably representing the same organism that acquired pBRZ01. Phylogenetic analysis (Figure 2) confirmed that VR-MSSA is not a derivative of VR-MRSA (1) (isolated days before from the same patient) and emphasized the relationship of this strain to other vancomycin-resistant S. aureus and MRSA isolates with intermediate susceptibility to vancomycin (VISA).
We analyzed the pool of cytoplasmic peptidoglycan precursors of VR-MSSA grown in the absence or presence of 50 μg/mL of vancomycin for induction of the vanA cluster (Table 2). Tandem mass spectrometry analysis identified 3 nucleotide precursors ending in
d-alanyl- d-alanine (UDP-MurNAc-pentapeptide), d-alanyl- d-lactate (UDP-MurNAc-pentadepsipeptide), and d-Ala (UDP-MurNAc-tetrapeptide). Upon induction with vancomycin, UDP-MurNAc-pentapeptide was not detected, and UDP-MurNAc-pentadepsipeptide accounted for most of the precursors (Table 2). These results indicate that the van-encoded enzymes required for incorporation of d-Lac into the precursors were fully functional in VR-MSSA. Our results also show that the vanA cluster was inducible by vancomycin in the S. aureus host because only a small proportion of the precursors (4%) ended in d-Lac in the absence of the drug.
Analyses of cell wall muropeptides from VR-MSSA showed 2 modifications of the
l-Ala1-γ- d-Glu2- l-Lys3- d-Ala4- d-Ala5 stem peptide that are highly conserved in S. aureus strains, namely the amidation of the α-carboxyl of d-Glu2 to form d-iGln2 and the addition of a pentaglycine side chain on the ε-amino group of l-Lys3 by the Fem amino-acyltransferases (9). Induction of the vanA gene cluster led to 2 major modifications. First, stem peptides ended in d-Ala4, indicating that the peptidyl- d-Ala4- d-Ala5 target of vancomycin, and d-Ala4- d-Lac5 termini, were fully eliminated. Second, the pentaglycine side chain was frequently missing (Technical Appendix[PDF - 745 KB - 11 pages]), indicating that replacement of d-Ala by d-Lac at the extremity of peptidoglycan precursors might have impaired the ability of Fem transferases to add Gly on l-Lys3.
In this study, we demonstrated that the vanA-containing pBRZ01 plasmid previously described in MRSA was acquired by an invasive MSSA isolate within the same patient. Our findings also suggest that a vanA-containing plasmid (pBRZ01) was horizontally acquired at least twice during a short period by distinct S. aureus lineages within the same host (MRSA belonging to ST8 and an ST5 MSSA). VR-MSSA belongs to the ST5 lineage of CC5, a major hospital-associated lineage (10). The prevalent hospital-associated lineages circulating in Brazil are ST5 (New York/Japan and Pediatric clones), ST239 (Brazilian clone) and ST1 (USA400 clone) (11), and recent epidemiologic data showed replacement of the endemic Brazilian (ST239) clone by ST5 strains (11–13). Moreover, VR-MSSA is related to ST5 vancomycin-resistant S. aureus strains recovered in the United States (8) and to VISA isolates, including Mu50 and the hetero-VISA strain Mu3, initially recovered in Japan (14). It remains unclear why CC5 strains appear more likely to exhibit vancomycin resistance.
Our biochemical analysis indicates that the vanA gene cluster is fully functional in VR-MSSA, which leads to vancomycin-inducible production of
d-Lac ending precursors and elimination of d-Ala- d-Ala containing peptidoglycan, as found in the enterococci (15). Our results also revealed a defect in side chain synthesis, although this did not prevent the synthesis of a functional and highly cross-linked peptidoglycan in VR-MSSA.
In summary, we report the in vivo acquisition of high-level vancomycin resistance in a bloodstream MSSA isolate. Of note, vanA-containing pBRZ01 was maintained even after the selective pressure of vancomycin had been removed, raising serious concerns about the possibility of further spread of resistance to this agent. However, no other MSSA strains containing this plasmid have been isolated so far in Brazil.
Dr. Panesso is a postdoctoral researcher at the Laboratory for Antimicrobial Research, University of Texas Medical School at Houston and associate professor of research at the Molecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia. Her research interests include the molecular aspects of antimicrobial resistance, with emphasis on gram-positive bacteria.
C.A.A. is supported by National Institutes of Health–National Institute of Allergy and Infectious Diseases (NIH-NIAID) grant R01 AI093749, B.E.M. is supported by NIH-NIAID grant R01 AI047923, and P.J.P. is supported by NIH-NIAID grant K08AI101005.
- Rossi F, Diaz L, Wollam A, Panesso D, Zhou Y, Rincon S, Transferable vancomycin resistance in a community-associated MRSA lineage. N Engl J Med.2014;370:1524–31.
- Reyes J, Rincon S, Diaz L, Panesso D, Contreras GA, Zurita J, Dissemination of methicillin-resistant Staphylococcus aureus USA300 sequence type 8 lineage in Latin America. Clin Infect Dis. 2009;49:1861–7.
- Tomita H, Pierson C, Lim SK, Clewell DB, Ike Y. Possible connection between a widely disseminated conjugative gentamicin resistance (pMG1-like) plasmid and the emergence of vancomycin resistance in Enterococcus faecium. J Clin Microbiol. 2002;40:3326–33.
- Arias CA, Panesso D, Singh KV, Rice LB, Murray BE. Cotransfer of antibiotic resistance genes and a hylEfm-containing virulence plasmid inEnterococcus faecium. Antimicrob Agents Chemother. 2009;53:4240–6.
- Benson MA, Ohneck EA, Ryan C, Alonzo F III, Smith H, Narechania A, Evolution of hypervirulence by a MRSA clone through acquisition of a transposable element. Mol Microbiol. 2014;93:664–81.
- Stamatakis A. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. Bioinformatics.2006;22:2688–90.
- Bouhss A, Josseaume N, Severin A, Tabei K, Hugonnet JE, Shlaes D, Synthesis of the L-alanyl-L-alanine cross-bridge of Enterococcus faecalispeptidoglycan. J Biol Chem. 2002;277:45935–41.
- Kos VN, Desjardins CA, Griggs A, Cerqueira G, Van Tonder A, Holden MT, Comparative genomics of vancomycin-resistant Staphylococcus aureusstrains and their positions within the clade most commonly associated with methicillin-resistant S. aureus hospital-acquired infection in the United States. MBio. 2012;3:e00112–12.
- Arbeloa A, Hugonnet JE, Sentilhes AC, Josseaume N, Dubost L, Monsempes C, Synthesis of mosaic peptidoglycan cross-bridges by hybrid peptidoglycan assembly pathways in gram-positive bacteria. J Biol Chem. 2004;279:41546–56.
- Nübel U, Roumagnac P, Feldkamp M, Song JH, Ko KS, Huang YC, Frequent emergence and limited geographic dispersal of methicillin-resistantStaphylococcus aureus. Proc Natl Acad Sci U S A. 2008;105:14130–5.
- Caboclo RM, Cavalcante FS, Iorio NL, Schuenck RP, Olendzki AN, Felix MJ, Methicillin-resistant Staphylococcus aureus in Rio de Janeiro hospitals: dissemination of the USA400/ST1 and USA800/ST5 SCCmec type IV and USA100/ST5 SCCmec type II lineages in a public institution and polyclonal presence in a private one. Am J Infect Control. 2013;41:e21–6.
- Dabul AN, Kos VN, Gilmore MS, Camargo IL. Draft genome sequence of methicillin-resistant Staphylococcus aureus strain SA16, representative of an endemic clone from a Brazilian hospital. Genome Announc. 2013;1:e00754–13.
- Teixeira MM, Araujo MC, Silva-Carvalho MC, Beltrame CO, Oliveira CC, Figueiredo AM, Emergence of clonal complex 5 (CC5) methicillin-resistantStaphylococcus aureus (MRSA) isolates susceptible to trimethoprim-sulfamethoxazole in a Brazilian hospital. Braz J Med Biol Res. 2012;45:637–43.
- Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Dissemination in Japanese hospitals of strains of Staphylococcus aureusheterogeneously resistant to vancomycin. Lancet. 1997;350:1670–3 .
- Arthur M, Depardieu F, Cabanie L, Reynolds P, Courvalin P. Requirement of the VanY and VanX D,D-peptidases for glycopeptide resistance in enterococci. Mol Microbiol. 1998;30:819–30 .
Suggested citation for this article: Panesso D, Planet PJ, Diaz L, Hugonnet J-E, Tran TT, Narechania A, et al. Methicillin-susceptible, vancomycin-resistantStaphylococcus aureus, Brazil. Emerg Infect Dis. 2015 Oct [date cited]. http://dx.doi.org/10.3201/eid2110.141914